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Anti-apoptotic BCL-2 family proteins such as Bcl-xL protect cells from death by sequestering 
apoptotic molecules, but also contribute to normal neuronal function. We find in hippocampal neurons that 
Bcl-xL enhances the efficiency of energy metabolism. Our evidence suggests that Bcl-xL interacts directly 
with the beta subunit of the F1FO ATP synthase, decreasing an ion leak within the F1FO ATPase complex 
and thereby increasing net transport of H+ by F1FO during F1FO ATPase activity. By patch clamping 
submitochondrial vesicles enriched in F1FO ATP synthase complexes, we find that, in the presence of ATP, 
pharmacological or genetic inhibition of Bcl-xL increases the membrane leak conductance. In addition, 
recombinant Bcl-xL protein directly increases ATPase activity of purified synthase complexes, while 
inhibition of endogenous Bcl-xL decreases F1FO enzymatic activity. Our findings suggest that increased 
mitochondrial efficiency contributes to the enhanced synaptic efficacy found in Bcl-xL expressing neurons. 
 
Introduction 
 
BCL-2 family proteins regulate programmed cell death1-3. In brain, neurons are eliminated during 
development, and after insults such as ischemia, infection or trauma1-3. The mechanisms by which anti-apoptotic 
proteins such as BCL-2 and Bcl-xL prevent death are incompletely understood. Bcl-xL sequesters pro-apoptotic 
members of the BCL-2 family and BH3-only proteins4-6. Additionally, Bcl-xL enhances metabolite exchange between 
mitochondria and the cytosol through interaction with VDAC, helping prevent release of death-promoting factors 7. 
Bcl-xL is often highly expressed in cancer cells resistant to cell death, but also functions in neuronal 
plasticity. Bcl-xL is the predominant anti-apoptotic protein in adult brain8. Over-expression of Bcl-xL increases the 
number and size of synapses, localizes mitochondria to presynaptic sites9 and increases mitochondrial biomass10. 
As synapses develop and grow, the formation of a larger reserve of neurotransmitter-containing vesicles 
contributes to more frequent or prolonged synaptic events11. The function of these larger pools of synaptic vesicles 
depends on metabolism and position of mitochondria at the synapse12. Certain mitochondrial-interacting proteins 
such as Drp1 and Bcl-xL participate in synaptic strengthening or vesicle recovery after high frequency firing 3, 12-14. 
Since high metabolic demand occurs during synaptic strengthening, a possible action of Bcl-xL is to increase the 
release or production of mitochondrial metabolites during synaptic plasticity.  
We have now found that neurons over-expressing Bcl-xL have higher ATP levels, and cells in which 
endogenous Bcl-xL is depleted or inhibited have lower ATP levels. Despite the increase in ATP, neurons over-
expressing Bcl-xL use less oxygen, while Bcl-xL depletion increases oxygen uptake. In addition to its outer 
membrane localization, we find Bcl-xL in the mitochondrial matrix by immuno-EM. Bcl-xL co-immunoprecipitates with 
the beta subunit of F1FO ATP synthase and binds to purified recombinant beta subunit of the F1 ATP synthase. 
Exogenously applied Bcl-xL increases F1FO ATPase activity, while Bcl-xL inhibition decreases enzymatic rate. Bcl-xL 
deficiency reduces the capacity of F1FO ATPase-containing submitochondrial vesicles to sequester H+ ions, 
suggesting that Bcl-xL depletion causes protons to leak upon activation of the enzyme. By patch clamping F1FO 
ATPase-containing vesicles exposed to ATP, we record an increased leak conductance when Bcl-xL is inhibited or 
depleted. We therefore suggest a model whereby Bcl-xL increases the efficiency of ATP synthesis by decreasing a 
proton leak within the F1FO ATPase, thus improving neuronal metabolism. 
 
RESULTS 
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ATP levels are elevated in Bcl-xL over-expressing neurons and decreased in Bcl-xL-depleted neurons. 
To determine the effect of Bcl-xL on ATP levels in neurons, luminescence of firefly luciferin/luciferase was 
measured in cultured hippocampal neurons expressing lentivirus constructs for GFP- Bcl-xL or control GFP15. ATP 
levels in GFP-Bcl-xL expressing cultures were approximately twice that of non-transduced or GFP-expressing 
controls (Fig. 1a, Fig. S1a). Knockdown of Bcl-xL with shRNA-carrying lentivirus but not with scrambled control virus 
decreased ATP levels (Fig. 1b,c), although cell death was not significantly different at the time of the study (Fig. 
S1b). As a further test of the effect of endogenous Bcl-xL on ATP levels, Bcl-xL activity was pharmacologically 
inhibited by ABT-737, a mimetic of BH3-only proteins that binds to Bcl-xL14, 16. ATP levels were decreased in 
cultures exposed to ABT-737 (Fig. 1d).  
Measurements of luminescence in lysed cells cannot accurately indicate ongoing levels of ATP production 
in live neurons. Therefore, to measure ATP levels in live neurons (excluding glia), neurons were engineered to 
express luciferase by lentiviral transduction (Fig.1d). Application of luciferin led to an immediate rise in 
luminescence (Fig. 1e calibrated to known concentrations of ATP). Such calibrated light levels were significantly 
higher in GFP-Bcl-xL expressing neurons compared to Mito-GFP controls (Fig. 1f).  
Elevated ATP levels in the Bcl-xL over-expressing cultures could be explained by an increase in aeorobic 
glycolysis. To determine if glycolysis is increased by Bcl-xL, lactate production was assessed by measuring lactate 
levels in the medium. Lactate level was significantly higher in controls compared to the Bcl-xL-expressing neurons, 
suggesting that Bcl-xL cells perform less glycolysis than controls (Fig. 1g). To further test the use of mitochondrial 
metabolism, cell viability was measured in a medium containing only mitochondrial substrates (Supple Fig 1c). 
GFP- Bcl-xL-over-expressing cells had improved survival compared to controls, suggesting enhanced mitochondrial 
competence. 
 
Bcl-xL decreases mitochondrial oxygen uptake.  
 Previous work described increased mitochondrial biomass in neurons over-expressing Bcl-xL10 (also see 
Fig. S2). If increased mitochondrial biomass were solely responsible for increased ATP levels, then Bcl-xL-
expressing cells would be expected to have increased oxygen uptake. To examine this, oxygen uptake was 
measured in single neurons in culture using a sensitive self-referencing oxygen electrode17 (Fig. 2a and Fig. 
S3a,b). Contrary to expectation, oxygen flux of Bcl-xL over-expressing neurons was lower than that of mito-GFP-
transfected neurons (Fig. 2b), suggesting that Bcl-xL over-expressing neurons couple ATP production more 
efficiently to oxygen uptake. Endogenous Bcl-xL has a similar effect because shRNA-mediated depletion (Fig. 2c,d) 
or pharmacological inhibition of Bcl-xL (Fig. 2e) increased oxygen flux by neurons. These data suggest that 
depletion/inhibition of Bcl-xL uncouples ATP production from oxygen uptake18-20. 
The higher ATP levels and lower oxygen uptake of Bcl-xL-over-expressing neurons could, in theory, result 
from a quiescent state where ATP accumulates due to reduced electrical and synaptic activity. This is unlikely 
because Bcl-xL over-expressing neurons have larger synapses and more spontaneous activity than controls9, 10. 
Therefore, we tested if Bcl-xL over-expressing neurons have a greater but underutilized energetic capacity. Bcl-xL 
over-expressing neurons increased oxygen flux by approximately 90% over basal when cells were depolarized with 
high potassium (High K), a treatment known to stimulate neuronal electrical and synaptic activity21, 22 (example 
shown in Fig. 2f) whereas Mito-GFP-expressing controls enhanced flux by only 50%. 
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During oxidative phosphorylation, protons pumped out of the mitochondrial matrix re-enter the matrix by 1) 
flux of H+ across the inner mitochondrial membrane at the ATP synthase (productive flux) and 2) a H+ leak (non-
productive)23. A decrease in the non-productive leak increases the efficiency of ATP production. To determine if 
Bcl-xL-over-expressing neurons have a different degree of non-productive leak across the inner membrane than 
controls during maximal activity, High K was rapidly washed out of the bath and oxygen uptake was measured in 
oligomycin, which inhibits H+ flux associated with ATP production, but does not inhibit H+ flux associated with the 
non-productive leak24. GFP-Bcl-xL cells had a higher ratio of productive oxygen flux to total oxygen flux compared to 
mito-GFP expressing controls, indicating that they use a higher percentage of the overall peak oxygen flux to make 
ATP (Fig. 2g). 
 
Bcl-xL enhances ATP synthesis during neuronal activity 
Neurons could regulate metabolism during periods of increased activity. To study the role of Bcl-xL in such 
enhanced energy production, we stimulated neurons with high K and measured cytosolic ATP levels 5min. after 
stimulation had ceased. Remarkably, levels of ATP were increased, suggesting a requirement for enhanced energy 
production that outlasted the period of stimulation. Such increase in ATP levels was completely prevented by pre-
exposure for 5 min. of the neurons to the Bcl-xL inhibitor ABT-737, suggesting that Bcl-xL was specifically required 
for the stimulation-induced metabolic change (Fig. 2h).  
 
Bcl-xL is localized to the mitochondrial inner membrane  
Previous studies have defined a role for Bcl-xL in releasing metabolites from mitochondrial outer 
membranes25, but a few studies have also suggested a localization of the related anti-apoptotic proteins Bcl-2 and 
Bcl-xL to the inner membrane26, 27 (including Chen and Hardwick, unpublished data). To confirm and extend these 
findings, we checked for mitochondrial localization of Bcl-xL in the Bcl-xL over-expressing hippocampal neurons and 
in control rodent brain, immuno-electron microscopy (immuno-EM) was performed. Bcl-xL was localized to the outer 
membrane and inner membrane/matrix of mitochondria of GFP- Bcl-xL expressing neurons (Fig. 3a) and native 
brain mitochondria (Fig. 3b). Furthermore, Bcl-xL (large gold beads) was co-localized at the inner membrane cristae 
with a known inner membrane cristae protein Manganese Super Oxide Dismutase (MnSOD; small gold beads, Fig. 
3b)28-30. Overall, Bcl-xL was localized about equally to inner membrane/matrix and to outer membrane (Fig. 3c). 
Reports also localize the anti-apoptotic protein BCL-2 or Bcl-xL in the same compartment as the beta-subunit of the 
ATP synthase (Chen and Hardwick, unpublished data)26, 27 or co-localize Bcl-2 with ANT31. To determine if Bcl-xL 
was indeed localized within this compartment, submitochondrial vesicles of the inner membrane that are enriched 
in F1FO ATP synthase protein complexes (SMVs) and lack an outer membrane were prepared from whole rat 
brain32, 33. Bcl-xL was present by immunoblot in this purified sample (Fig. S4). To further localize Bcl-xL within the 
inner membrane, the protein was co-immunoprecipitated with the ATP synthase complex beta-subunit using either 
a specific antibody against Bcl-xL or a specific antibody against ATP synthase beta-subunit (Fig. 3d). To determine 
the exact binding site of Bcl-xL, recombinant FLAG- and myc-tagged proteins of the ATP synthase subunits alpha, 
beta, c, d, delta, epsilon, gamma and OSCP were immunoprecipitated from mammalian 293T cells using beads 
conjugated to anti-FLAG antibody. Endogenous Bcl-xL co-immunoprecipitated only with alpha and beta subunits 
(Fig. 3e). The interaction with beta-subunit was blocked by the specific Bcl-xL inhibitor ABT-737, suggesting that the 
beta-subunit binds to Bcl-xL within the ABT-737 binding pocket (Fig. 3f). 
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Recombinant Bcl-xL protein enhances enzymatic rate of the F1FO ATPase 
To determine if Bcl-xL affects enzymatic activity of F1FO ATPase, the rate of ATP hydrolysis was quantified 
in SMVs32, 33. Vesicles were treated with triton-x to isolate the F1FO ATPase enzyme complex from the membrane. 
Activity of the F1FO ATPase was prevented by the ATP synthase inhibitor oligomycin, confirming the specificity of 
the reaction to the F1FO ATPase complex (Fig. 4a). Addition of recombinant Bcl-xL protein increased the rate of ATP 
hydrolysis (Fig. 4a) over that measured after addition of control protein (bovine serum albumin (BSA), suggesting 
that interaction of Bcl-xL protein with the F1FO ATPase increases enzymatic rate. Bcl-xL protein itself had no effect 
on luciferase activity in the absence of SMVs (1.000 +/- 0.008 vs. 0.994 +/- 0.006 without and with Bcl-xL, 
normalized to controls, N=5 wells each). In addition, the N terminus of Bcl-xL was not required, since recombinant 
Bcl-xL protein lacking the N-terminus (DeltaN Bcl-xL) also increased the rate of ATP hydrolysis (Fig. S5a). To test if 
endogenous Bcl-xL contributed to enzymatic rate, F1FO ATPase was exposed to ABT-737. ABT-737 decreased the 
rate of ATP hydrolysis (Fig. 4b), while DMSO carrier had no effect (Fig. S5b; N=3).  
The enzymatic activity of the F1FO ATPase was also measured in an ATP-regenerating assay where ATP 
concentration cannot be rate-limiting. Recombinant Bcl-xL protein significantly enhanced the enzymatic rate of the 
F1FO ATPase; inactive Bcl-xL protein had no effect (Fig. 4c); ABT-737 and another small molecule inhibitor of Bcl-xL, 
Obatoclax34 significantly decreased enzymatic rate. The effect of Bcl-xL was mimicked by application of a 
recombinant truncated Bcl-xL protein lacking the membrane-targeting region (Delta-TM Bcl-xL), indicating that 
specific membrane targeting is not necessary for this effect (Fig. 4c). These studies suggest that endogenous or 
exogenously applied Bcl-xL enhance enzymatic rate of the F1FO ATPase, and that the N and C termini are not 
required for these effects. Furthermore, there was no change in the rate of ATP hydrolysis upon exposure to 
membrane ionophores, nystatin or FCCP, (N=3 samples each, Fig. S5c), suggesting that the channel-producing 
function of Bcl-xL is not responsible for the enhanced enzymatic rate of F1FO ATPase.  
 
Bcl-xL inhibition attenuates H+ sequestration into submitochondrial vesicles during F1FO ATPase activity. 
The oxygen flux studies had revealed an oligomycin-insensitive, Bcl-xL-sensitive leak of H+ that could 
contribute to inefficiency of ATP production. To measure H+ leak during F1FO ATPase enzymatic activity, we 
measured movement of H+ ions into the SMVs in response to ATP hydrolysis. After addition of ATP to the SMVs, 
ATPase activity results in a decrease in H+ concentration in the bath surrounding the vesicles35 measured by a 
decrease in fluorescence of the SMV-excluded H+ indicator, ACMA35 (Fig. 5a). Addition of ATP to the control buffer 
in the absence of SMVs failed to change ACMA fluorescence (99.2 +/-1% control, N=6) whereas addition of ATP to 
SMVs resulted in a marked decrease in fluorescence (Fig. 5b,c). Attenuation of the maximum response to ATP 
occurred either upon inhibition of H+ ion import through the FO pump (oligomycin), or by leakage of H+ out of the 
SMVs (FCCP). Attenuation also occurred in the presence of two different small molecule Bcl-xL inhibitors, ABT-
73716 or Obatoclax34 (Fig. 5b,c), consistent with the hypothesis that inhibition of endogenous Bcl-xL decreases 
enzymatic rate and/or induces a H+ leak within the SMV membrane. 
 
Patch clamp recordings of submitochondrial vesicles reveal a Bcl-x-L-sensitive membrane leak.  
To more directly measure leak conductance, we developed a method to patch clamp the SMVs isolated 
from native rat brain. This method was based on our previous published methods in which we had patch-clamped 
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similarly sized organelles (500-1000nm in diameter) either within living presynaptic terminals or isolated from brain, 
using pipettes with diameters of ~180nm3, 36, 37. In intracellular solution lacking ATP in both the bath and pipette, a 
giga-ohm seal was formed on the isolated SMVs, then currents recorded while holding the membrane at different 
voltages between -150mV and + 150mV. The peak conductance was 600pS on average. In some (Fig. 6a, left) but 
not all (Fig. 6c, left) recordings, gating between different levels of conductance was detected. Since SMVs perform 
ATP hydrolysis coupled to H+ movement upon addition of ATP to the vesicles (see Fig. 5), and the F1 portion of the 
F1FO ATPase faces the medium in the preparation32, we reasoned that addition of ATP during recordings might 
produce a measurable current. In contrast, however, 0.5mM ATP consistently resulted in decreased membrane 
conductance of the SMVs by approximately 70% (Fig. 6a,c middle, mean data shown in second bar in Fig. 6b,d). 
The decrease in conductance most likely represents closure of channels and an increase in resistance caused by 
the effects of ATP on the membrane in series with the patched membrane.  
The ATP effect suggests an ATP-responsive leak conductance associated with the F1FO ATPase. To 
determine if the change in leak conductance occured during ATP synthesis, succinate and ADP were added to 
mimic the conditions present during ATP synthesis. The decrease in membrane conductance was similar to that 
with ATP (N=3, conductance decreased by 79+/- 8%, p < 0.02, paired t test), suggesting that the leak conductance 
was equally sensitive to ADP or ATP. 
To assess the role of Bcl-xL in determining mitochondrial membrane leak conductance, Bcl-xL was inhibited 
pharmacologically. Both ABT-737 and Obatoclax increased the conductance in the SMV membranes when added 
in the presence of ATP (Fig. 6a-d), although the leak was not affected by addition of control buffer (0.1% DMSO, 
Fig. S6a) or addition of ABT-737/Obatoclax in the absence of ATP (Fig. 6b,d), indicating that the inhibitors 
themselves do not cause a leak.  
To confirm the results obtained with pharmacological inhibition, knockdown of Bcl-xL using shRNA 
lentiviruses was performed on cultured hippocampal neurons. Knockdown of Bcl-xL was confirmed with 
immunoblots (Fig. 6e). Similar to non-transduced controls, SMV patch recordings made from scrambled shRNA-
expressing cultures responded to ATP application with approximately 80% decrease in peak conductance 
(measured from 0pA; Fig. 6f,g), while conductances from SMVs of Bcl-xL shRNA transduced cultures had 
approximately 50% reduction (Fig. 6g,h). This suggests that endogenous Bcl-xL is required for full leak closure upon 
ATP binding. Further studies showed that the Bcl-xL-regulated leak conductance in SMVs is different from the 
oligomycin-sensitive H+ conductance and is pharmacologically distinct from that of the ANT or KATP (Fig. S6b-g). A 
non-selective proteinaceous pore that shunts H+ ions away from H+ translocating activities found within the 
membrane portion of the F1FO ATPase protein complex is a reasonable candidate for the ATP/ Bcl-xL-regulated 
leak conductance. 
 
Bax/Bak-independent cell survival depends on Bcl-xL-regulated metabolic changes. 
The anti-apoptotic function of Bcl-xL can exist independently of interaction with pro-apoptotic Bcl-2 family 
members such as Bax and Bak38, but the mechanism of such protection is not fully understood. Glucose-free, 
galactose-containing media force mitochondrial metabolism. To address if the metabolic function and the Bax/Bak 
independent survival function of Bcl-xL overlapped, we studied the effects on ATP levels and cell survival of over-
expression of Bcl-xL in Bax, Bak double knockout (DKO) mouse embryonic fibroblasts (MEFs). ATP levels 
increased over time in Bcl-xL expressing cells on galactose medium (Fig. S7a). The change in medium decreased 
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survival of the MEFs; Bcl-xL over-expression enhanced survival suggesting that increased mitochondrial ATP 
production by Bcl-xL may rescue cells from metabolic compromise in the absence of Bax or Bak (Fig. S7b). 
 
DISCUSSION 
  
 Previous studies show that Bcl-xL increases mitochondrial biomass9, 10. Therefore, it was surprising to find 
that resting neurons expressing Bcl-xL use less oxygen but have higher ATP levels and reduced glycolysis. 
Stimulated Bcl-xL-expressing neurons use more of the total oxygen uptake for ATP production than stimulated 
controls. Additionally Bcl-xL acutely increases ATP production during neuronal stimulation, because ABT-737 
completely prevents such increase. These findings suggest that neuronal activity induces Bcl-xL-dependent 
changes in mitochondrial metabolism. In stimulated neurons, Bcl-xL expressed on endoplasmic reticulum (ER) 
membranes might influence the directed release of ER calcium toward mitochondrial calcium uptake mechanisms 
that could further enhance ATP synthesis39.  
 Our evidence supports a Bcl-xL/ATP-modulated H+ leak in the inner mitochondrial membrane that reduces 
efficiency. 1) An ATP-sensitive leak of H+ measured with the H+ indicator ACMA is re-activated by pharmacological 
inhibitors of Bcl-xL, 2) patch clamp recordings of SMVs reveal a large ion conductance attenuated by ATP, and 
reactivated by pharmacological or genetic inhibition of Bcl-xL. The leaky membrane of control SMVs may come 
about by preparation of the vesicles without adenine nucleotides, but an adenine nucleotide-deficient state could 
also exist under pathophysiological conditions such as ischemia or neurodegenerative disorders. Re-introducing 
ATP/ADP rapidly closes the leak suggesting that ATP/ADP-induced leak closure is an integral aspect of enzymatic 
function.  
 Although increased ATP synthase enzymatic activity will not in and of itself increase efficiency, 
recombinant Bcl-xL protein and the Bcl-xL inhibitors regulate enzymatic rate as measured by two assays (Fig. 4). 
These results raise the possibility that a change in position of certain proteins within the F1FO ATPase/synthase 
complex regulates enzymatic rate and leak closure. 
 Bcl-xL has been found previously to act at the outer membrane 40-43. How Bcl-xL might target to the inner 
membrane is not known. Reports have located the related protein Bcl-2 or Bcl-xL to the inner membrane26, 44 in the 
same compartment as the beta subunit of the ATP synthase27 (and Chen and Hardwick unpublished data), and 
have suggested that Bax requires the F1FO ATPase to initiate apoptosis45, and that oligomycin suppresses 
apoptosis46. The current study confirms and extends these findings, localizing Bcl-xL to the beta subunit by immune-
electron microscopy, by co-immunoprecipitation with the F1FO ATPase, and by co-immunoprecipitation with purified 
mammalian alpha and beta subunits. Binding of Bcl-xL to the beta subunit is reversed by ABT-737, suggesting that 
the ABT-737 binding region is needed for binding to the beta subunit. In keeping with this, mutant recombinant Bcl-
xL proteins lacking the BH4 domain (N terminus) or the membrane targeting domain (C terminus) act as effectively 
as the full length protein to increase the rate of ATP hydrolysis. 
 The protein responsible for the leak channel itself is as yet unidentified. Only a few of the F1FO 
ATPase/synthase- proteins have been characterized33, 47. Other ATP-sensitive candidate channels of the inner 
membrane include the ANT, Mito KATP and members of the UCP family20, 48-52. Although up-regulation of UCP 
activity in brain enhances neuroprotection, levels of homologues of the UCPs in healthy brain are relatively low 53-55. 
It is therefore likely that we have encountered a novel conductance within the F1FO ATPase/synthase. 
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 The increase in ATP production by Bcl-xL over-expressing healthy neurons was anticipated by studies 
showing an increase in release of ATP and phosphocreatine in Bcl-xL over-expressing non-neuronal cells 
undergoing death 7, 56. Protection from cell death was attributed to enhanced release of ATP from mitochondria 
through Bcl-xL-regulated VDAC opening in the outer membrane. Our results do not preclude Bcl-xL activity in the 
outer membrane. In fact, it is likely that enhanced ATP production by the inner membrane F1FO ATP synthase 
complex requires maintaining VDAC in an open configuration to release the newly synthesized ATP into the 
cytosol. 
 Enhanced metabolic efficiency by Bcl-xL in neurons may produce resistance to death of tumor cells57, 58 and 
enhancement of cell survival shown here is independent of Bax and Bak (Fig. S7). Some tumor cells manifest 
metabolic changes attributed to an increase in aerobic glycolysis59-61. We show that healthy neurons use Bcl-xL to 
produce a different kind of metabolic efficiency. Nevertheless, the changes in metabolism produced by Bcl-xL could 
enhance resistance to pathological stressors including hypoxia and substrate deprivation and could maintain 
cytosolic ATP levels in the face of increased energy demand provided by synaptic development, and long- or short-
term changes in synaptic plasticity. 
 
Methods 
Primary cultures of rat hippocampal neurons and transfections. Primary rat hippocampal neurons were 
prepared as described previously62, 63 and were transfected with 2.5 M calcium phosphate at DIV5 with an efficiency 
of ~1-5%. Neurons were transduced with lentiviral construct at DIV4-8 and studied at DIV10-14 with an efficiency of 
near 100%. 
Viral constructs. Lentiviruses expressing Bcl-xL with an N terminal GFP tag were used to transduce cultured 
hippocampal neurons, achieving almost 100% efficiency. Expression of GFP-Bcl-xL facilitates determination of 
protein levels by Western blotting with an anti-GFP antibody (Anti-GFP Product #06-896 Upstate,1:500). Full length 
GFP-Bcl-xL was subcloned into a lentiviral vector c-FUW64. Viral constructs were packaged in 293T cells by co-
transfection with packaging plasmid delta 8.9 and envelope plasmid VSVG.48, and at 60h after transfection, virus-
containing supernatant was collected and used to transduce cultured hippocampal neurons. Transduced neurons 
were studies at ~7 days after transduction. 
Lentiviral shRNA knockdown of Bcl-xL. The lentiviral plasmids, expressing short hairpin RNAs (shRNA) were 
from Open Biosystems, USA. The hairpin sequence against rat Bcl-xL was: 
CGGGCTCACTCTTCAGTCGGAATAGTGAAGCCACAGATGTATTCCGACTGAAGAGTGAGCCCA 
For control, the scrambled, nonsilencing shRNA sequence (Open Biosystems catalog no. RHS4346) was used. 
Viruses were produced according to published methods65. The pGIPZ vector, containing either shRNA sequence 
against Bcl-xL or the scrambled sequence was co-transfected with the packaging ∆8.9 and the vesicular stomatitis 
virus G protein vectors into HEK 293T cells. The supernatant was purified after 72h and added to the hippocampal 
cultures. The isolation of ATP F1FO ATPases was carried out 4 days after viral transduction of the neurons. 
Luciferase assay for in vitro ATP and ADP measurements. Cellular ATP levels were measured upon acute cell 
membrane lysis in a plate reader (Perkin-Elmer) in the presence of Luciferin/luciferase (ApoSENSOR, Biovision, 
Mountain View, CA). Luminescence values were normalized to protein concentration for each well (performed by 
Pierce BSA method). 
Cytosolic ATP-luminescence measured in situ. To continually monitor cytosolic ATP in intact cells, hippocampal 
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neurons (E19) were transduced with a luciferase (firefly) lentiviral vector on DIV-4. The CSCW2-Luc-IRES-EGFP 
vectors were co-transfected into 293T cells with lentiviral packaging genome and envelope. Approximately 106 viral 
particles were used per 14mm coverslip containing between 104-105 cells. Neurons were also co-transfected with 
plasmid DNA for either MitoGFP (control) or BCLxL-EGFP (efficiency of >50%) using magnetofection66 (NeuroMag; 
OZ Biosciences)9. Between 4-7 days incubation, Neurobasal growth media (Invitrogen) was replaced with warm 
ACSF containing (in mM): NaCl (120), KCl (3.1); KH2PO4 (0.4); HEPES (pH 7.4; 20; NaHCO3 (5); NaSO4 (1.2); 
CaCl2 (1.3); glucose (5.5) and 1mM D-luciferin (Na salt; BD BioSciences). Light output from neurons was assessed 
in a custom-built, heated (37o) luminometer that includes a computer-controlled UNIBLITZ high-speed electronic 
shutter (Vincent Associates, NY) and photo-multiplier tube (R464; Hamamatsu Photonics). 0.5mM luciferin or 
greater generated maximum light output for a given coverslip. Once steady state light output had been reached, 
mitochondrial ATP production was inhibited with oligomycin (10mg/ml). After 15min, ATP-dependent light levels 
were normalized for ATP by permeabilizing the neurons with a mock intracellular buffer67. Luciferase expression in 
neurons was verified by imaging single neurons for light output with a high-intensity CCD (C5405-50; Hamamatsu 
Photonics) mounted on an inverted microscope (Axiovert 135 TV; Carl Zeiss Inc.). A 40x oil-immersion objective 
with high numerical aperture (Fluar; Carl Zeiss Inc.) was used to ensure efficient light capture. Photons were 
integrated using custom-built acquisition software (BioCurrents Research Center). 
Oxygen flux measurements. Oxygen uptake was measured in single neurons in culture using a sensitive oxygen 
electrode17. Oxygen flux was recorded using a 2-4µm dia. electrode at 5µm from the cell that was moved with a 
displacement of 10µm in the X-Y axes so that the oxygen-sensing electrode was positioned repeatedly closer to 
and farther from the cell. The current detected at two positions results in a differential current that can be translated 
into oxygen flux given the known oxygen concentration in the bath and the distance of the excursion of the 
electrode between the two points (Fig. S1A, B)17. The measured current associated with oxygen flux across the 
neuronal membrane was lower after treatment with oligomycin (Fig. S1B). The measured current was further 
lowered by treatment of cells with the electron transport inhibitor antimycin A (Fig. S1B). For oxygen flux 
measurements performed during neuronal activity, cells were perfused with osmotically-balanced extracellular 
solution containing high KCl (90mM KCl, 64mM NaCl, 2mM MgCl2, 10mM glucose, 10mM HEPES, 2mM CaCl2 
(pH 7.4, 300 mOsm) for one minute followed by cessation of perfusion for one minute during which peak oxygen 
flux was measured. Cells were again perfused with normal extracellular buffer (KCl lowered to 2.5mM) for one 
minute, followed by addition of oligomycin (20 mg/ml) to the bath. Oxygen flux was measured after cessation of 
perfusion and reaching a stable value for at least 5 min.  
 F1FO ATPase vesicle preparation. Rodent whole brain without cerebellum was minced in isolation buffer (IB 
(250mM sucrose, 20mM Hepes, pH 7.2, 1mM EDTA, BSA 0.5%)). Tissue was homogenized in a Dounce 
homogenizer, then centrifuged at low speed (1300rcf-set tabletop to 4000) to pellet nuclear material. Supernatant 
was centrifuged at high speed (13,000rcf) to pellet mitochondria and synaptosomes. Synaptosomes were disrupted 
with a nitrogen decompression chamber (Parr Instruments, Moline, Illinois) at 1,200psi for 10min, followed by rapid 
decompression. Mitochondrial and burst synaptosomes were layered onto ficoll gradients (10% and 7.5% ficoll) and 
centrifuged in Beckman ultracentrifuge at 32,500rpm for 20min. Pellet was washed and resuspended in IB (approx. 
4-10 mg/mL protein), combined with an equal volume of digitonin (Dig 1% = 10 mg/mL isobuffer), incubated on ice 
for 15min and centrifuged twice at 9000xg for 10min. Pellet was resuspended in 200μL of IB, and 2μL of 10% 
Lubrol PX (C12E9)(Calbiochem, San Diego, CA) was added, mixed, and allowed to sit on ice for 15min. 
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Lubrol/mitochondria mixture was layered onto IB and centrifuged at 39,000rpm for 1hr. Final pellet was washed in 
IB and centrifugated at 13,000rpm. 
Luciferase assay on F1FO ATPase. ATP hydrolysis was measured using the BioVision Aposensor ATP Assay Kit, 
according to manufacturer’s protocol in presence of 30-40μg F1FO ATPase, and 0.5mM ATP. In some experiments, 
10µL Bcl-xL .045-0.79 mg/ml, 5µg/ml Oligomycin, 1µM FCCP, nystatin (450mg/ml), 17μM ABT-737, or 0.1% DMSO 
were added to the mixture. Data are displayed as mM ATP hydrolysis/min./mg SMV protein. All experiments used 3 
wells for each condition, and the experiments were repeated at least three times for each condition on samples 
from different F1FO ATPase isolations. 
ATP synthase enzyme activity assay. The ATPase activity was measured using the assay kit from Mitosciences, 
USA (Catalog # MS541), according to the manufacturer’s protocol and published methods68. Briefly, 5mg F1FO 
ATPase/synthase (per well) was detergent-extracted and immunocaptured overnight within the 96 well plates. 
Inhibitors of Bcl-xL were added to the immobilized enzyme and incubated for 20min. prior to addition of the reagent 
mix and measurement. The oxidation of NADH to NAD+ results from a coupled reaction catalyzed by pyruvate 
kinase and lactate dehydrogenase in presence of phosphoenolpyruvate, dependent on ADP production by the 
ATPasein the presence of ATP. The change in fluorescence as NADH is oxidized was measured as a decrease in 
absorbance at 340nm using a PerkinElmer VICTOR3 Multilabel Plate Reader. 
Electrophysiology. F1FO ATPase vesicle recordings were made by forming a giga-ohm seal onto F1FO ATPase 
vesicles in intracellular solution (in mM: 120 KCl, 8 NaCl, 0.5 EGTA, 10 HEPES, pH 7.3) using an Axopatch 200B 
amplifier (Axon Instruments) at room temperature (22–25°C). Recording electrodes were pulled from borosilicate 
glass capillaries (WPI) with a final resistance in the range of 80-120 MW. SMVs were visualized by phase-contrast 
microscopy with a Nikon or Zeiss inverted microscope. Signals were filtered at 5 kHz using the amplifier circuitry. 
Data were analyzed using pClamp 10.0 software (Axon Instruments). All population data were expressed as mean 
± SEM. Membrane currents under different experimental conditions were assessed by measuring peak membrane 
current (in pA) – the baseline current. The baseline current was defined as a non-specific electrode leak current. All 
current measurements were adjusted for the holding voltage assuming a linear current-voltage relationship: The 
resulting conductances are expressed in pS according to the equation G= V/DI where G is conductance in pS, 
V=membrane holding voltage in mV, DI = peak membrane current in pA - baseline current. Group data were 
quantified in terms of conductance. 
ATP-driven quenching of 9-Amino-6-chloro-2-methoxyacridine (ACMA). ACMA fluorescence quenching was 
measured according to previously published methods69. 2µM ACMA (Sigma-Aldrich, USA) was added to 5µg 
isolated F1FO ATPase vesicles47, in presence of ATP (1mM), inhibitors of Bcl-xL, Oligomycin or FCCP at 
concentrations described in the text (total volume of 100µl). F1FO ATPase vesicle suspensions were excited at 
410nm, and emission was measured at 490nm, using a PerkinElmer VICTOR3 Multilabel Plate Reader. 
Electron microscopy Hippocampal neuron cultures (DIV13-14) prepared from E18 embryonic rats were 
transduced with lentiviruses expressing GFP or GFP-Bcl-xL fusion protein to achieve gene expression in 
approximately 100% of the neurons9, and at 7 days post infection, cultures were prepared for electron microscopy 
as previously described9. 
Immuno-electron microscopy Samples (either cultured cells or whole brain) were fixed in 4% paraformaldehyde 
in 0.25M Hepes for 1 hour. Cultured cells were scraped and re-suspended in 10% gelatin. Samples were rinsed in 
PBS, chilled and trimmed to smaller blocks then placed in 2.3M sucrose overnight on a rotor at 4oC. Brain tissue 
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was cut into small pieces and placed in 2.3M sucrose overnight on a rotor at 4oC. Samples were then transferred to 
aluminum pins and frozen rapidly in liquid nitrogen. The frozen block was trimmed on a Leica Cryo-EMUC6 
UltraCut and 65-75nm thick sections were collected using the Tokoyasu method70. The frozen sections were 
collected on a drop of sucrose, thawed and placed on a nickel formvar/carbon coated grid and floated in a dish of 
PBS ready for immunolabeling. Grids were placed section side down on drops of 0.1 M ammonium chloride for 
10min to quench untreated aldehyde groups, then blocked on 1% fish skin gelatin in PBS for 20mins. Single 
labeled grids were incubated on either a primary antibody rabbit anti-Bcl-x (Biocarta) 1:50, or mouse anti-Sod2 
(Abnova) 1:150 dilutions for 30mins. A rabbit anti mouse bridging antibody (Jackson) was used for the mouse 
primaries before rinsing and using 10nm protein-A gold (UtrectUMC) for 30mins. Double labeled grids used the 
primary rabbit anti-Bcl-x and 10 nm protein-A gold followed by the mouse anti-Sod/rabbit anti-mouse bridge and the 
5nm protein-A gold. All grids were rinsed in PBS, fixed using 1% gluteraldehyde for 5mins, rinsed and transferred to 
a UA/methylcellulose drop for 10mins. Samples were viewed with a FEI Tencai Biotwin TEM at 80Kv. Images were 
taken using Morada CCD and iTEM (Olympus) software. 
Immunoprecipitation and Western blot analysis. Cell lysate was incubated with 2µg rabbit anti anti- Bcl-xL 
(54H6, Cell Signaling) and mouse anti-beta-subunit (Mitosciences) antibodies in RIPA buffer overnight at 4ºC with 
gentle rocking. Protein G sepharose beads (Sigma-Aldrich) were added and incubated overnight at 4ºC. Following 
(3X) washing with the lysis buffer, the bound proteins were eluted from the beads with 2X Laemmli sample buffer. 
The immunoprecipitated samples were analyzed by Western blotting. For the Bcl-xL-synthase interaction study, the 
human ORF constructs for alpha, beta, b, c, delta, d, epsilon, gamma and OSCP ATP-synthase subunits, tagged 
with Myc and DDK (Flag), from Origene Technologies (Rockville, MD), were expressed in 293T cells and purified, 
using the EZview^™ Red ANTI-FLAG^® M2 Affinity Gel (Sigma, USA), according to the manufacturer’s protocol. 
The expression was verified and the binding of Bcl-xL to individual subunits was assessed by immunoblot analysis, 
using the mouse anti-Myc and Rabbit anti-Bcl-xL antibodies (Cell signaling Technology), respectively. 
Western blotting for mitochondrial protein was carried out using the following antibodies: rabbit anti-human Bcl-xL 
(A.G.Scientific, 1:1000), anti-GFP antibody (ab290, Abcam, 1:1000), rabbit anti-Drp1 (sc-32898, Santa Cruz, 
1:1000), rabbit anti-VDAC (#4866, Cell Signaling, 1:1000), mouse anti-GAPDH, (sc-32233, Santa Cruz, 
1:1000),rabbit anti-ANT (sc-11433, Santa Cruz, 1:1000), rabbit anti-PGC1alpha, (#2178, Cell signaling, 1:1000), 
mouse anti-COXIV, (ab14744, abcam, 1:1000). 
Lactate measurements. Lactate was measured by enzyme-controlled fluorometric assay for NADPH-NADP 
conversion, after the method of Lowry and Passoneau (1972), using a CMA600 analyser (CMA/Microdialysis, 
Solna, Sweden). 
Statistical analysis. For comparisons involving 2 groups, paired or unpaired Student’s t-tests (2-tailed) were used. 
In all figures, *=p<0.05, **=p<0.01, and ***=p<0.001 to denote significance level, and exact p values are provided in 
the figure legends. 
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Figure legends 
 
Figure 1. Cellular ATP levels are altered by Bcl-xL over-expression or depletion in hippocampal neurons  
 15 
a. ATP levels as measured by firefly luciferin/luciferase luminescence at 7 days after transduction with lentivirus 
constructs. Luminescence level was normalized to protein level in each individual well, N= 8 wells, ***p < 0.0001). 
At least three independent experiments of different cultures showed similar results. 
b. Western blot for endogenous Bcl-xL protein. Cell lysates prepared from non-transduced control hippocampal 
neuron cultures (CTL), scrambled shRNA expressing neuron cultures and Bcl-xL shRNA expressing neuron 
cultures at 4 days after viral transduction. GAPDH serves as a loading control. 
c. ATP levels as measured by firefly luciferin/luciferase luminescence in control cultures or cultures expressing Bcl-
xL shRNA or scrambled shRNA at 4 days after viral transduction. Luminescence level was normalized to protein 
level in each individual well (N=11 for each condition, representing two independent cultures; *p<0.03). 
d. ATP levels as measured by firefly luciferin/luciferase luminescence in control cultures or cultures exposed for 12-
18 hrs to ABT-737 at the indicated concentrations. Luminescence level was normalized to protein level in each 
individual well (N=15 for each condition, **p<0.004 ***p<0.0001, three independent cultures). 
e. Example image of a neuron expressing CSCW2-Luciferase lentiviral vector. Light is produced in response to 
application of 1mM luciferin. Shown are phase, luminescent and overlay images. In pseudocolor images, blue is 
low luminescence, yellow is high luminescence. Scale bar: 20µm. 
f. Group data for amount of ATP represented by luminescence per coverslip of living hippocampal neurons at 7 
days after transfection with indicated constructs. Light levels were normalized to average of light levels in mito-GFP 
control cells. Living neurons were transfected with CSCW2-luciferase-IG lentivirus vector and mito-GFP or GFP- 
Bcl-xL (N= 8 coverslips from at least three independent cultures for mito-GFP-expressing neurons, N=10 coverslips 
from at least three independent cultures of GFP-Bcl-xL expressing neurons, * P < 0.02).  
g. Lactate levels in medium surrounding GFP-Bcl-xL expressing neurons compared to GFP expressing controls 
after 12 hrs in physiological (5mM) glucose medium (one culture, N=3 replicates for each condition *p< 0.02). For 
all panels error bars indicate SEM. 
 
Figure 2. Bcl-xL alters oxygen uptake by neurons. Resting Bcl-xL over-expressing and Bcl-xL depleted 
neurons have altered oxygen uptake. 
a. Photomicrograph of self-referencing amperometric O2 microsensor positioned next to a single hippocampal 
neuron. Scale bar: 20µm.  
b. Group data for basal respiration in GFP- Bcl-xL expressing neurons compared with Mito-GFP expressing neurons 
at 7 days after transfection (N=28 Mito-GFP expressing neurons, N=26 GFP- Bcl-xL expressing neurons; 
***p<0.0005). Experiment was repeated in 5 different cultures from 5 different animals. 
c. Representative traces of oxygen flux levels of single neurons. For neuronal flux measurements, self-referencing 
amperometric O2 microsensor was placed within 1µm of the cell surface. For background measurement, electrode 
was moved 200µm from the cell surface. 
d. Group data for basal respiration levels of single non-expressing neurons, or neurons expressing Bcl-xL shRNA or 
scrambled shRNA at 7 days after viral transduction (N=10 replicates for CTL and Bcl-xL shRNA, N=9 replicates for 
scrambled shRNA, at least three independent cultures were used for studies; *p<0.05). 
e. Group data for basal respiration levels of single control neurons or neurons exposed for 18 hrs to 10µM ABT-737 
(N=26 for control and 19 for ABT-737; **p< 0.002; at least three different cultures for each group). 
f. Representative traces of oxygen flux levels of single neurons expressing Bcl-xL-GFP or mito-GFP, while resting 
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(a), stimulated with 90mM KCl (b) and after addition of 5mg/ml oligomycin (c). All values were normalized against 
the average oxygen flux of the same neuron at resting flux level. 
g. Group data for the oxygen flux of single cultured neurons expressing Bcl-xL-GFP or mito-GFP. Leak-subtracted 
oxygen flux was divided by peak oxygen flux measured during neuronal activity [ratio = (b-c)/b]. Neurons were 
studied from four independent cultures (N=9 Mito-GFP control neurons, N=12 GFP-Bcl-xL expressing neurons, 
*p<0.04). 
h. Luminescence of firefly luciferase in cultured hippocampal neurons exposed or not to 1µM ABT-737 for 5 min. 
and subsequently stimulated with 90mM KCl for 90s (N=12 wells per group; ***p<0.0001; two different cultures for 
each condition). Measurement of stimulated wells was taken 5min. after washout of high K. For all panels error bars 
indicate SEM. 
 
Figure 3. Bcl-xL is expressed in the mitochondrial inner membrane and interacts with ATP synthase. 
a. Immuno-electron micrographs from cultured neurons over-expressing Bcl-xL at 7 days after viral transduction. 
Bcl-xL immunoreactivity in the outer membrane (left panel, arrow) and the inner membrane cristae (right panel, 
arrow) are shown. Scale bars: 200nm. 
b. Immuno-EM prepared from untreated rat brain (large balls: Bcl-xL; small balls: MnSOD). 
c. Average number of immunogold particles per electron micrograph representing Bcl-xL protein in the outer vs. 
inner membrane (N=30 micrographs). Error bars indicate SEM. 
d. Reciprocal immunoblots of co-immunoprecipitation of Bcl-xL and ATP synthase beta-subunit from purified rat 
brain ATP synthase complex. Antibodies are as indicated (IB) (N=3). Top lane: the precipitating antibodies were 
IgG and Bcl-xL. The top right lane represents the whole cell lysate. Bottom lane: the precipitating antibodies were 
IgG and ATP synthase betasubunit. The bottom right lane represents the whole cell lysate. 
e. Immunoprecipitation of the Myc-Flag-tagged ATP synthase subunits (Alpha, Beta, b, c, Delta, D, Epsilon, 
Gamma, and Oscp), precipitated using the anti-Flag affinity gel and immunoblotted using anti-myc tag antibody 
(upper panel). (Lower panel): Western blot analysis, using anti-Bcl-xL antibody, on the immunoprecipitated 
samples. 
f. Immunoprecipitation of the Myc-Flag-tagged ATP synthase subunit Beta, precipitated using the anti-Flag affinity 
gel and immunoblotted using anti-myc tag antibody (upper panel). Cells were pre-exposed for 12hr to 1µM ABT-
737 or vehicle. (Lower panel): Western blot analysis, using anti-Bcl-xL antibody on the immunoprecipitated samples. 
 
Figure 4. Bcl-xL protein regulates ATPase activity. 
a. Luminescence of firefly luciferin/luciferase activity in the presence of ATP. N=3 wells without F1FO ATP synthase 
(blank); N=3 wells F1FO ATP synthase plus the FO inhibitor oligomycin (5 mg/ml); N=6 wells synthase plus 
recombinant Bcl-xL protein (0.045-0.79 mg protein/ml); N=9 wells synthase plus control protein (0.05 mg/ml BSA, 
F1FO ATP synthase concentration for all experiments was 4 mg protein/ml). *p < 0.05, **p < 0.005, ***p<0.0005. 
Experiments on Bcl-xL vs. control were repeated and confirmed on 5 different experimental days using at least two 
different F1FO ATPase vesicle preparations (from two different animals). 
b. F1FO ATPase activity of purified F1FO ATP synthase in the absence and presence of ABT-737 (20µM). Data are 
displayed as percent change in fluorescence over time (N=3 for each condition; ***p< 0.0008, **p<0.003, *p<0.04). 
Experiments were repeated on three independent isolations with similar results.  
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c. F1FO ATPase activity of the purified F1FO ATP synthase vesicles in the presence of the indicated recombinant 
proteins or reagents as a function of the rate of decrease in NADH fluorescence (see Methods). (Left panel) N=3 
samples in each condition, **p<0.002,*p<0.04, assay performed with similar results on two independent F1FO ATP 
synthase isolations. (Right panel) N=7 samples for each condition, assay performed with similar results on two 
independent isolations***p<0.0001. For all panels error bars indicate SEM. 
 
Figure 5. ATP-sensitive H+ ion sequestration into F1FO ATPase vesicles (SMVs) is attenuated by Bcl-xL 
inhibitors, and by oligomycin and FCCP.  
a. Arrangement of F1FO ATPase vesicle exposed to the fluorescent pH indicator, ACMA. ATP binds to F1 to activate 
ATP hydrolysis and drives H+ ions through FO, decreasing ACMA fluorescence. Bcl-xL inhibitors produce an H+ leak 
out of the F1FO ATPase membrane, perhaps at the site of the F1FO ATPase itself, resulting in an increase in ACMA 
fluorescence. Oligomycin blocks movement of H+ ions through the FO, and thus prevents a drop in ACMA 
fluorescence. FCCP is an H+ ionophore that causes the leakage of H+ out of the SMV. 
b. Example traces of fluorescence changes of ACMA indicator over time in the presence of F1FO ATPase vesicles 
(N=3 samples for each condition, repeated three times. Comparing effects of reagents in the presence of ATP to 
the effect of ATP alone, * p < 0.05; ** p < 0.01; ***p < 0.0001, one-way ANOVA).  
c. Group data showing peak effect on relative fluorescence (% control). Control represents fluorescence of ACMA 
indicator in the presence of SMVs before the addition of ATP (N=3 samples for each group. * p < 0.05; ***p<0.0001, 
one-way ANOVA. This study was repeated at least three times on different batches of SMVs with similar results. 
Error bars indicate SEM. 
 
Figure 6. Pharmacological inhibition or depletion of Bcl-xL reverse leak closure in patch clamp recordings 
of isolated ATP F1FO ATPase vesicles.  
a. Example SMV patch recording at the indicated voltage before and after ATP and ATP/ABT-737 exposure. Dotted 
line represents 0pA. 
b. Group data of membrane conductances of all recordings such as shown in a (SMV recordings from left to right, 
N=30, 23, 19, 7; **p< 0.002, ***p<0.0009). The last histogram shows experiments in which the Bcl-xL inhibitor was 
added to patches in the absence of ATP.  
c. Example SMV patch recording at the indicated voltage before and after ATP and ATP/Obatoclax exposure. 
Dotted line represents 0 pA. 
d. Group data of membrane conductances of all recordings such as shown in c (SMV recordings from left to right, 
N=23, 9, 15, 14; **p< 0.004, *p<0.04). The last histogram shows experiments in which the Bcl-xL inhibitor was 
added to patches in the absence of ATP.  
e. Western blot for endogenous Bcl-xL protein. Cell lysates prepared from non-transduced control hippocampal 
neuron cultures (CTL), scrambled shRNA expressing neuron cultures and Bcl-xL shRNA expressing neuron 
cultures at 4 days after transduction. Protein concentration was controlled by immunoblotting for GAPDH. 
f. SMV patch recordings before and after the addition of 0.5mM ATP. SMVs were prepared from hippocampal 
neurons expressing control (scrambled) shRNA at 4 days after transduction. 
g. Group data from all recordings of control (scrambled) shRNA or Bcl-xL shRNA. Shown is the membrane leak 
conductance remaining after the addition of ATP as a percent of the initial conductance before the addition of ATP 
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(N=5 control recordings, N=7 shRNA Bcl-xL recordings; *p< 0.03). 
h. SMV patch recordings before and after the addition of ATP. SMVs were prepared from hippocampal neurons 
expressing Bcl-xL shRNA at 4 days after transduction. For all panels error bars indicate SEM. 
 
Figure S1 
a. ATP levels for different densities of neuron plating; low (n=12 wells for each condition), medium (n=4 wells each 
condition), medium-high (n=4 wells each condition) and high (n=3 wells each condition); experiments were from two 
independent cultures (***p< 0.0001 for GFP- Bcl-xL compared to control or GFP). 
b. Number of total cells, green fluorescent cells, and green fluorescent cells with pyknotic nuclei (stained with DAPI) 
per field at 4 d after transduction in cultures of hippocampal neurons transduced with GFP-Bcl-xL shRNA or 
scrambled GFP-shRNA (n=23 from 4 cultures per condition). 
c. Percent cell death of GFP- Bcl-xL over-expressing cultures vs. GFP expressing cultures in media lacking glucose 
containing only mitochondrial substrates (5mM methylpyruvate and 5mM methylsuccinate). Dead cells are 
expressed as a percentage of the total number of cells (one culture; N=14 different plates for each condition of 
GFP- Bcl-xL vs. GFP, ***p< 0.0001). For all panels error bars indicate SEM. 
 
Figure S2 
a. Examples of low power electron micrographs of GFP or GFP- Bcl-xL expressing cultures.  
b. Group data for total mitochondrial area in low power images of cells in GFP- Bcl-xL expressing neurons vs. GFP 
expressing neurons at 7 days after transduction (***p<0.0001, N=2 images for each condition, a total of 673 regions 
of interest were measured for GFP- Bcl-xL, 853 for GFP). Mitochondrial area in GFP- Bcl-xL expressing neurons is 
approximately 50% increased over controls. 
c. Examples of high power electron micrographs of somata of GFP or GFP- Bcl-xL expressing cultures.  
d. Group data for measurements in somata (**p<0.005, 9 micrographs of GFP, 124 mitochondrial measurements 
compared to 10 micrographs of GFP- Bcl-xL, 205 mitochondrial measurements). The data indicate that 
mitochondria area is increased in the somata, not only in the neuronal processes. 
e. Cellular protein amounts and amount of a mitochondrial transcription factor. Shown are representative Western 
blots of cell lysates from GFP or GFP- Bcl-xL expressing hippocampal cultures.  
f. Quantification of protein levels for the indicated protein. The optical densities of the bands of proteins from GFP- 
Bcl-xL expressing cultures were normalized to the density of a control protein (GAPDH), then expressed as a fold 
increase over the densities in GFP expressing cultures (N=3 separate cell cultures for each group; **p, 0.02). 
g. Quantification of protein levels for the indicated protein. The optical densities of the bands of proteins from GFP- 
Bcl-xL expressing cultures were normalized to the density of a control protein (GAPDH), then expressed as a fold 
increase over the densities in GFP expressing cultures (N=3 separate cell cultures for each group; *p, 0.05). The 
data indicate that mitochondrially-associated proteins are increased in GFP- Bcl-xL expressing cultures over 
controls, consistent with mitochondrial biogenesis due to Bcl-xL over-expression. For all panels error bars indicate 
SEM. 
  
Figure S3  
a. Oxygen flux level is indirectly proportional to distance of the oxygen recording electrode from the cell (N=3 cells). 
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Error bars indicate SEM. 
b. Representative current recording from a self-referencing O2 sensor. The current is proportional to the O2 gradient 
established by a respiring cell, falls after treatment with the ATP synthase inhibitor oligomycin and is almost 
completely removed with the respiratory chain inhibitor antimycin.  
 
Figure S4 
Examples of western blots of purified SMVs immunoblotted with the indicated antibodies. Last lane represents 
recombinant Bcl-xL protein. 
 
Figure S5 
a. Luminescence of firefly luciferin/luciferase activity in the presence of ATP. N=3 wells F1FO ATP synthase plus 
control protein (0.05 mg/ml BSA); N=3 wells F1FO ATP synthase plus recombinant deltaN Bcl-xL protein (1.8mg 
protein/ml); F1FO. ATP synthase concentration for all experiments was 4mg protein/ml). Experiments were repeated 
and confirmed on 3 different experimental days using at least two different F1FO ATPase vesicle preparations (from 
two different animals).  
b. F1FO ATPase activity in the absence and presence of 0.1% DMSO. Luminescence of firefly luciferin/luciferase 
activity in the presence of ATP (N=3 wells in each group. Experiment repeated three times on two different 
preparations of SMVs with similar results). 
c. F1FO ATPase activity in the absence and presence of FCCP (1µM) and nystatin (10µM). Luminescence of firefly 
luciferin/luciferase activity in the presence of ATP (N=3 wells in each group). For all panels error bars indicate SEM. 
 
Figure S6 
a. Example of SMV patch recording before and after 0.1% DMSO. 
b. Example SMV recordings before and after ATP, then after oligomycin (5 mg/ml final).  
c. Group data for ATP-exposed SMV patch recordings before and after the addition of oligomycin (N=13 separate 
SMV recordings before and after oligomycin, **p<0.01, paired t test). Shown is the mean membrane conductance in 
both conditions after baseline leak subtraction. Because the effect of oligomycin is not occluded by pre-treatment 
with ATP, the data indicate that the ATP-sensitive conductance in SMVs is different from the oligomycin-sensitive 
proton conductance. 
d. Group data for SMV patch recordings before and after the addition of oligomycin, then ATP. Shown is the 
membrane conductance after baseline leak subtraction (N=7 recordings; *p<0.02). Note that the oligomycin-
sensitive conductance is not present in the absence of ATP. 
e. Group data for ATP-exposed SMV patch recordings before and after the addition of Bongkrekic acid (BA; 10µM 
final), a membrane permeable inhibitor of ANT. Shown is the membrane conductance in both conditions after 
baseline leak subtraction (N=6 recordings). The data indicate that the ATP-regulated leak conductance is 
pharmacologically distinct from that of ANT. 
f. Group data for SMV patch recordings indicate that ATP is effective after the application of BA (N=6 before and 
after BA; N=3 to which ATP was added. 
g. Another conductance of the inner membrane that is sensitive to ATP is that of KATP. A known inhibitor of KATP 
channels, glibenclamide (1µM), had no effect on the conductance of the patches (N=3), suggesting that KATP was 
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also not responsible for the ATP-sensitive conductance in the F1FO ATPase vesicle recordings shown in Figs. 6. 
For all panels error bars indicate SEM.  
 
Figure S7 
a. ATP levels measured by luminescence of firefly luciferase in Bax-/-;Bak-/- MEFs expressing the indicated 
constructs measured at 0, 5, 10hrs after change to galactose-containing, glucose-free medium (N=6 wells; *p < 
0.05; experiments confirmed by two independent experiments). For each time point, measurements are normalized 
to the average of the control data. 
b. Cell survival measured at 5 and 24hrs after switching to galactose-containing, glucose-free medium. MEFs are 
expressing the indicated constructs (N=7 wells for each condition; **p < 0.01, ***p < 0.001; experiments confirmed 
by two independent experiments). For all panels error bars indicate SEM. 
 
Figure S8 
Uncropped images of films for the key experiments in the main figures. 
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